Literature DB >> 20567917

Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation.

Israel Gomy1, Greice Andreotti Molfetta, Ester de Andrade Barreto, Cristiane Ayres Ferreira, Dalila Luciola Zanette, José Cláudio Casali-da-Rocha, Wilson Araujo Silva.   

Abstract

von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary cancer syndrome that predisposes to the development of a variety of benign and malignant tumours, especially cerebellar haemangioblastomas, retinal angiomas and clear-cell renal cell carcinomas (RCC). The etiology and manifestations are due to germline and somatic mutations in the VHL tumour suppressor gene. VHL disease is classified into type 1 and type 2, showing a clear genotype-phenotype correlation, as type 2 is associated with phaeochromocytoma and essentially caused by missense mutations. The aim of this study is to characterize the phenotype and genotype of families with VHL disease. Eighteen of twenty patients from ten unrelated families underwent genetic testing, nine of them fulfilled VHL disease criteria and one had an apparently sporadic cerebellar haemangioblastoma. Four different germline mutations in the VHL gene were identified: c.226_228delTTC (p.Phe76del); c.217C > T (p.Gln73X); IVS1-1 G > A and IVS2-1 G > C. The first three mutations were associated with type 1 disease and the last one with type 2B, which had never been identified in the germline. The transcriptional processing of a novel splice-site mutation was characterised. Three type 1 VHL families showed large deletions of the VHL gene, two of them encompassed the FANCD2/C3orf10 genes and were not associated with renal lesions. We also suggest that such families should be subclassified according to the risk of RCC and the extent of the VHL gene deletions. This study highlights the need for a through clinical and molecular characterisation of families with VHL disease to better delineate its genotype-phenotype correlation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20567917     DOI: 10.1007/s10689-010-9357-2

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  24 in total

1.  Detection of germline deletions using real-time quantitative polymerase chain reaction in Japanese patients with von Hippel-Lindau disease.

Authors:  Keiko Hattori; Jun-ichi Teranishi; Catherine Stolle; Minoru Yoshida; Kei-ichi Kondo; Takeshi Kishida; Hiroshi Kanno; Masaya Baba; Yoshinobu Kubota; Masahiro Yao
Journal:  Cancer Sci       Date:  2006-05       Impact factor: 6.716

2.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

3.  Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan.

Authors:  B Zbar; T Kishida; F Chen; L Schmidt; E R Maher; F M Richards; P A Crossey; A R Webster; N A Affara; M A Ferguson-Smith; H Brauch; D Glavac; H P Neumann; S Tisherman; J J Mulvihill; D J Gross; T Shuin; J Whaley; B Seizinger; N Kley; S Olschwang; C Boisson; S Richard; C H Lips; M Lerman
Journal:  Hum Mutat       Date:  1996       Impact factor: 4.878

4.  Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma.

Authors:  S Olschwang; S Richard; C Boisson; S Giraud; P Laurent-Puig; F Resche; G Thomas
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

5.  Genotype-phenotype correlations in VHL exon deletions.

Authors:  Alisdair McNeill; Eleanor Rattenberry; Richard Barber; Pip Killick; Fiona MacDonald; Eamonn R Maher
Journal:  Am J Med Genet A       Date:  2009-10       Impact factor: 2.802

6.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

Authors: 
Journal:  J Clin Oncol       Date:  2003-04-11       Impact factor: 44.544

7.  Von Hippel-Lindau disease: a genetic study.

Authors:  E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

8.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

9.  Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions.

Authors:  Catherine Gallou; Dominique Chauveau; Stéphane Richard; Dominique Joly; Sophie Giraud; Sylviane Olschwang; Natacha Martin; Céline Saquet; Yves Chrétien; Arnaud Méjean; Jean-Michel Correas; Gérard Benoît; Pierre Colombeau; Jean-Pierre Grünfeld; Claudine Junien; Christophe Béroud
Journal:  Hum Mutat       Date:  2004-09       Impact factor: 4.878

10.  Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations.

Authors:  E R Maher; A R Webster; F M Richards; J S Green; P A Crossey; S J Payne; A T Moore
Journal:  J Med Genet       Date:  1996-04       Impact factor: 6.318

View more
  8 in total

1.  Genotype phenotype correlation in Asian Indian von Hippel-Lindau (VHL) syndrome patients with pheochromocytoma/paraganglioma.

Authors:  Nilesh Lomte; Sanjeet Kumar; Vijaya Sarathi; Reshma Pandit; Manjunath Goroshi; Swati Jadhav; Anurag R Lila; Tushar Bandgar; Nalini S Shah
Journal:  Fam Cancer       Date:  2018-07       Impact factor: 2.375

2.  Genotype-phenotype analysis of von Hippel-Lindau syndrome in fifteen Indian families.

Authors:  Narendranath Vikkath; Sindhu Valiyaveedan; Sheela Nampoothiri; Natasha Radhakrishnan; Gopal S Pillai; Vasantha Nair; Ginil Kumar Pooleri; Georgie Mathew; Krishnakumar N Menon; Prasanth S Ariyannur; Ashok B Pillai
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

3.  A meta-analysis of different von Hippel Lindau mutations: are they related to retinal capillary hemangioblastoma?

Authors:  Fatemeh Azimi; Ali Aghajani; Golnaz Khakpour; Samira Chaibakhsh
Journal:  Mol Genet Genomics       Date:  2022-08-25       Impact factor: 2.980

4.  A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.

Authors:  S Cingoz; R B van der Luijt; E Kurt; M Apaydin; I Akkol; Mihriban Heval Ozgen
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

5.  Clinical presentation of Von Hippel Lindau syndrome type 2B associated with VHL p.A149S mutation in a large Turkish family.

Authors:  T Mete; D Berker; E Yilmaz; G Ozgen; Y Yalcin; M Tuna; D Ciliz; M Onen; Y Aydin; S Guler
Journal:  Endocrine       Date:  2013-05-15       Impact factor: 3.633

6.  Clinical presentation and mutation analysis of VHL disease in a large Chinese family.

Authors:  Qing Zhang; De-Ling Li; Peng Kang; Nan Ji; Jun Yang; Wei-Ming Liu; Li-Wei Zhang; Gui-Jun Jia
Journal:  J Neurooncol       Date:  2015-09-04       Impact factor: 4.130

Review 7.  Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: not a needle in a haystack.

Authors:  João Castro-Teles; Bernardo Sousa-Pinto; Sandra Rebelo; Duarte Pignatelli
Journal:  Endocr Connect       Date:  2021-10-27       Impact factor: 3.335

8.  Frequent Mutations of VHL Gene and the Clinical Phenotypes in the Largest Chinese Cohort With Von Hippel-Lindau Disease.

Authors:  Baoan Hong; Kaifang Ma; Jingcheng Zhou; Jiufeng Zhang; Jiangyi Wang; Shengjie Liu; Zhongyuan Zhang; Lin Cai; Ning Zhang; Kan Gong
Journal:  Front Genet       Date:  2019-09-18       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.